The development and implementation of polygenic risk scoring algorithms for stratifying individuals for future cognitive decline due to Alzheimer's Disease in non-symptomatic and early cognitive impaired subjects

本项目将评估基于遗传的风险分层在认知正常受试者和轻度认知障碍（MCI）受试者中对未来认知下降的效用。MCI可能是AD（阿尔茨海默病）的前驱状态，并且这些患者中的50-60%处于进展为AD的高风险中，然而，目前AD的预后方法在早期MCI中仅准确25-30%。缺乏有效的生物标志物阻碍了这些患者的临床管理，也阻碍了对阿尔茨海默病有用的新疗法的开发。该项目将研究大量患者和认知正常受试者，以证明一组已确定的高危AD生物标志物的有效性。这样的预后测试是必不可少的，使紧急AD治疗的有意义的临床试验。

This project will evaluate the utility of genetic based risk stratification for future cognitive decline in cognitively normal subjects and those with Mild Cognitive Impairment (MCI). MCI may be a prodromal state for AD (Alzheimer's Disease) and 50-60% of these patients are at high risk of progression to AD, however current prognostic methods for AD are only 25-30% accurate in early MCI. The lack of validated biomarkers hampers clinical management of these patients and also the development of new therapies useful in Alzheimer's Disease. This project will study large cohorts of patients and cognitively normal subjects to demonstrate the validity of a panel of identified at-risk AD biomarkers. Such a prognostic test is essential to enable meaningful clinical trials of emergent AD therapies.